Please login to the form below
Ongentys
This page shows the latest Ongentys news and features for those working in and with pharma, biotech and healthcare.
Neurocrine bags FDA approval for first tardive dyskinesia drug
The COMT inhibitor was approved in Europe as Ongentys last June as an adjunct to Parkinson's disease treatment, and Neurocrine is hoping to meet with the FDA to see what
Latest news
-
EC approves Bial’s Parkinson’s disease therapy
Manufactured by Bial, Ongentys (opicapone) is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adults with Parkinson's and end-of-dose motor fluctuations who cannot ... Bial says its drug will be
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
-
Account Director
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Account Manager
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Associate Director
-
£75, 000-90, 000
-
Account Manager / Account Director
-
Competative
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- Welcome to the Communique Awards - Communiqué Awards 2018
- NICE rejects Novartis migraine treatment Aimovig
- GSK upbeat on its return to oncology market
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- AZ’s Sean Bohen to exit after business overhaul; report
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
- Escaping the spin cycle of sub-optimal launch
- ...
Quick links
Infographics
